Vigene Biosciences recently opened its $20 million, state-of-the-art lab and research facility and global headquarters in Rockville, MD. Vigene provides viral vector-based gene delivery services and products with the goal of making gene therapy affordable. The company streamlines virus production from early conceptual stages to commercial manufacturing. The new 71-thousand square foot facility, combines new manufacturing technologies and high yield production cell lines with the rigorous quality of cGMP and BSL-3.

Read More: Exclusive Interview with Dr. Jeffrey Hung, Chief Commercial Officer of Vigene Biosciences